核磁共振與超音波影像融合切片於攝護腺癌之診斷：3年經驗分享

吳志緯¹、何肇晏¹、邱文祥^1,2、何承勳^1,2、黃一勝^1,2、蔡德甫^1,2、葉忠信^1,2、莊光達^1,2、鄭以弘¹、仇光宇^1,2、陳宏恩¹、林鉅棟¹、李秉叡¹

1.新光吳火獅紀念醫院外科部泌尿科

2.輔仁大學

MRI-US Fusion Prostate Biopsy in Diagnosis of Prostate Cancer: A Preliminary Experience of 3 Years

Chih-Wei Wu ¹, Chao-Yen Ho ¹, Allen W. Chiu ^1,2, Chen-Hsun Ho^1,2, Thomas I.S. Hwang^1,2, Te-Fu Tsai^1,2, Chung-Hsin Yeh^1,2, Guang-Dar Juang^1,2, Yi-Hong Cheng¹, Kuang-Yu Chuo^1,2, Hung-En Chen¹,Chu-Tung Lin¹, Bin-Rui Lee¹

1.Division of Urology, Department of Surgery, Shin Kong WHS Memorial Hospital, Taipei, Taiwan

2.Fu-Jen Catholic university, New Taipei, Taiwan

Purpose:

MRI-US fusion biopsy has been introduced for enhancing accuracy of prostate diagnosis. Our objective is to analyze our data in MRI-US fusion biopsy and to determine cancer detection rate in each procedure in a single institution.

Materials and Methods:

We retrospectively reviewed total 92 procedures from 2021 to 2023 in the Shin Kong Wu Ho-Su Memorial Hospital. In each procedure, we collected PSA level, highest target PIRADs categories and pathological outcomes. After excluding PSA level >20, we analyze overall cancer rate and cancer rated based on PIRADS categories in subgroup of PSA between 4-20 in the first year and the second year.

Results:

From 2021 to 2023, 92 procedures were performed. Mean PSA level is 13.55 ± 17.17 ng/mL. Overall cancer detection rate is 46.7% (43/92 patients). Cancer rate is 48.44% in PIRADS ≧3 and 63.27% in PIRADS ≧4. In the first year of group 4-20, overall cancer rate is 39% and cancer rate is 44%, 100% in PIRADS ≧3, PIRADS ≧4 respectively. In the second year, overall cancer rate is 47% and cancer rate is 47%, 83% in PIRADS ≧3, PIRADS ≧4 respectively.

Conclusion: